Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens is a research paper published in JCI Insight (2021). On theSindex it has a DataRank of 1.1. It has been cited 31 times, with 19 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.520
From this paper's citation signal
Citation Network Contribution
0.575
From 16 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 19 citers.
National Institutes of Health
Grant: NIH P30 CA023100,NIH R01 CA226803
NCI NIH HHS
Grant: P30 CA023100
NCI NIH HHS
Grant: R01 CA226803
FDA HHS
Grant: R01 FD006334
FWCI
3.41
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals